Novo Nordisk Chief Signals Openness to Wall Street Listing as Oral Obesity Bet Takes Shape

CEO Mike Doustdar says Novo Nordisk is "fundamentally open" to a direct NYSE listing, as the drugmaker bets oral therapies could take half the obesity market by 2030.

Novo Nordisk is leaving the door open to a direct listing on the New York Stock Exchange, a move that would retire its American depositary receipts in favor of ordinary shares traded on Wall Street. CEO Mike Doustdar told the Financial Times in an interview published Wednesday that the Danish drugmaker is "fundamentally open" to such a step, though he was quick to temper expectations of anything imminent.

The strategic musing arrives alongside a broader repositioning of the company's obesity franchise. In separate remarks to Reuters on Tuesday, Doustdar predicted that oral therapies could capture as much as half of the global obesity market by 2030 — a striking forecast that signals a departure from the weekly injection products that have defined the category so far.

A Shareholder Base That Has Drifted West

The rationale for a US listing rests on a simple demographic shift. Over the past two decades, Novo Nordisk's investor base has steadily migrated away from Scandinavia, while more than half of group revenue is now generated in the United States. That is also where the bulk of Wegovy and Ozempic sales are booked. A direct NYSE listing could lower barriers for institutional American investors, mirroring a path already taken by UK rival AstraZeneca earlier this year.

Even so, Doustdar made clear that no active work is underway. The idea has circulated internally for years, but he said there has been no live dialogue with exchange representatives since he took the helm last year. Copenhagen remains the company's primary trading venue for the foreseeable future. Shares edged up 0.8% to EUR 34.73 in pre-market trading on the back of the interview.

Pipeline Targets Meet a Skeptical Market

The listing discussion lands in a more uncomfortable stretch for the stock. At Monday's capital markets day, management set out ambitions to bring more than five blockbuster medicines to market by 2030 and to generate over DKK 150 billion in pipeline revenue by 2035. Analysts, however, pressed on pricing power and M&A strategy, according to Reuters, and the shares came under pressure in the aftermath. The stock currently trades at EUR 34.32, sitting 37% below its 52-week high.

That drawdown reflects a competitive landscape that has grown considerably harsher. Data from LSEG indicates that sales of Eli Lilly's Zepbound are expected to outpace Wegovy by more than USD 7 billion this year. Against that backdrop, Novo Nordisk's pivot toward tablet-based treatments carries real strategic weight — oral formats could reach patient populations that injectables cannot, but only if the company can defend its pricing.

The Pricing Question That Will Define the Decade

How much margin survives the shift from high-priced injectable niches to mass-market pills is the central valuation question. If Novo Nordisk can open new patient segments without a dramatic collapse in revenue per treatment, the business model stays highly profitable. If health systems and insurers extract steep discounts on oral products, the margin erosion that market watchers fear becomes reality. The DKK 150 billion pipeline revenue target for 2035 hinges directly on whether the company can hold its innovation premium beyond the end of the decade.

Management is hedging its bets through partnerships. A recently signed agreement with Orbis Medicines covers oral cardiometabolic therapies, while a research collaboration with Anthropic points to a growing emphasis on computational approaches. Should these efforts bear fruit, Novo Nordisk could dominate the transition to tablets and overshoot its own revenue ambitions.

Cannibalization and Deal Risk on the Other Side

The bear case is not hard to construct. A faster-than-expected migration from weekly shots to daily pills risks cannibalizing existing blockbusters, and oral manufacturing and logistics demand different capabilities — giving competitors room to close the gap and spark price wars. Filling the pipeline with more than five new blockbusters by 2030 will also require external acquisitions and costly licensing deals. If takeovers prove more expensive than planned or clinical setbacks materialize, capital discipline could wobble, and the valuation premium the market has long afforded Novo Nordisk may shrink further.

Milan Becomes the Next Proving Ground

Near-term direction depends on whether the stock can hold its recent floor. As long as no further target cuts follow, the pipeline narrative leaves room for a fundamental re-rating. A continued slide in sentiment over US pricing, however, would risk extending the medium-term downtrend.

The next hard catalyst is already scheduled. Novo Nordisk will present data at the annual meeting of the European Association for the Study of Diabetes (EASD), running from September 28 to October 2 in Milan. Those disclosures should offer the clearest read yet on how durable the company's plans for the next generation of obesity therapies really are.